Search research articles
Contact Us
Filters
Showing results (1-10 of 148) with videos related to
Page
of 15
Sort By:
BJU International
|
September 14, 2007
Additional treatment for pT3 prostate cancer: now, later or never
David P Dearnaley
The Lancet. Oncology
|
February 7, 2015
Hypofractionated radiotherapy in prostate cancer
David P Dearnaley
International Journal of Radiation Oncology, Biology, Physics
|
March 31, 2004
In regard to "The return of the snake oil salesman" (IJROBP 2003;55:561-562, and 56:1507-1508)
David P Dearnaley
Future Oncology (London, England)
|
August 19, 2021
Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer
Daniel J George, David P Dearnaley
Frontiers of Radiation Therapy and Oncology
|
January 5, 2002
Prostate cancer--the Royal Marsden conformal experience
Christopher M Nutting, David P Dearnaley
Expert Review of Anticancer Therapy
|
July 11, 2009
Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?
Scott C Morgan, David P Dearnaley
The Lancet. Oncology
|
March 4, 2021
Intermediate clinical endpoints in localised prostate cancer
Alison C Tree, David P Dearnaley, Emma Hall
Current Oncology Reports
|
March 27, 2017
The Role of Hypofractionated Radiotherapy in Prostate Cancer
Linus C Benjamin, Alison C Tree, David P Dearnaley
Cancer Management and Research
|
December 5, 2015
Rationale and development of image-guided intensity-modulated radiotherapy post-prostatectomy: the present standard of care?
Julia R Murray, Helen A McNair, David P Dearnaley
European Urology
|
March 8, 2016
Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21-30
Alison C Tree, Nicholas J van As, David P Dearnaley
Page
of 15
Search research articles
Search
Showing results (1-10 of 148) with videos related to
Sort By:
Page
of 15
BJU International
|
September 14, 2007
Additional treatment for pT3 prostate cancer: now, later or never
David P Dearnaley
The Lancet. Oncology
|
February 7, 2015
Hypofractionated radiotherapy in prostate cancer
David P Dearnaley
International Journal of Radiation Oncology, Biology, Physics
|
March 31, 2004
In regard to "The return of the snake oil salesman" (IJROBP 2003;55:561-562, and 56:1507-1508)
David P Dearnaley
Future Oncology (London, England)
|
August 19, 2021
Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer
Daniel J George, David P Dearnaley
Frontiers of Radiation Therapy and Oncology
|
January 5, 2002
Prostate cancer--the Royal Marsden conformal experience
Christopher M Nutting, David P Dearnaley
Expert Review of Anticancer Therapy
|
July 11, 2009
Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?
Scott C Morgan, David P Dearnaley
The Lancet. Oncology
|
March 4, 2021
Intermediate clinical endpoints in localised prostate cancer
Alison C Tree, David P Dearnaley, Emma Hall
Current Oncology Reports
|
March 27, 2017
The Role of Hypofractionated Radiotherapy in Prostate Cancer
Linus C Benjamin, Alison C Tree, David P Dearnaley
Cancer Management and Research
|
December 5, 2015
Rationale and development of image-guided intensity-modulated radiotherapy post-prostatectomy: the present standard of care?
Julia R Murray, Helen A McNair, David P Dearnaley
European Urology
|
March 8, 2016
Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:21-30
Alison C Tree, Nicholas J van As, David P Dearnaley
Page
of 15